Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 7/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 7/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | PRCP | P42785 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18323717 | 1.00 | MEN1 (0.50) | MEN1POLBKMT2ACHRM2CHRM1 | |
| SCHEMBL22953317 | 1.00 | MEN1 (0.50) | MEN1POLBKMT2ACHRM2CHRM1 | |
| SCHEMBL9191084 | 0.95 | MEN1 (0.45) | MEN1POLBKMT2ACHRM2CHRM1 | |
| SCHEMBL19554733 | 0.95 | MEN1 (0.45) | MEN1POLBKMT2ACHRM2CHRM1 | |
| SCHEMBL12918863 | 0.89 | MEN1 (0.58) | MEN1POLBKMT2ACHRM2CHRM1 | |
| SCHEMBL9705183 | 0.89 | MEN1 (0.58) | MEN1POLBKMT2ACHRM2CHRM1 | |
| SCHEMBL28154335 | 0.87 | CA2 (0.35) | MEN1POLBKMT2AKDM4ECYP3A4 | |
| SCHEMBL8530912 | 0.87 | CA2 (0.35) | MEN1POLBKMT2AKDM4ECYP3A4 | |
| SCHEMBL24177721 | 0.87 | BLM (0.42) | MEN1POLBKMT2ABLMPMP22 | |
| SCHEMBL9481973 | 0.87 | BLM (0.42) | MEN1POLBKMT2ABLMPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217978-A1 | COMPOUND AS ADENOSINE A2a RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2024-07-04 | — | — | US | disclosed |
| US-20240217978-A1 | COMPOUND AS ADENOSINE A2a RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2024-07-04 | — | — | US | disclosed |
| CN-117813334-A | Onium salt, blocking agent dissociation catalyst for blocking isocyanate, blocked isocyanate composition containing blocking agent dissociation catalyst, thermosetting resin composition, cured product, and method for producing same | 广荣化学株式会社 | 2024-04-02 | — | — | CN | disclosed |
| US-11713361-B2 | Hydrogenation catalyst compositions and their use for hydrogenation of nitrile rubber | ARLANXEO DEUTSCHLAND GMBH (DE) | 2023-08-01 | — | — | US | disclosed |
| CN-112548113-A | Preparation method of silver nanoparticles | 中国科学院深圳先进技术研究院 | 2021-03-26 | — | — | CN | disclosed |
| US-20180075978-A1 | PHOTOELECTRIC CONVERSION DEVICE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-03-15 | — | — | US | disclosed |
| US-20150352108-A1 | AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF TBK1 AND/OR IKK EPSILON | ALZHEIMER'S INSTITUTE OF AMERICA (US) | 2015-12-10 | — | — | US | disclosed |
| US-20120238540-A1 | AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF IKK EPSILON AND/OR TBK1 | MYREXIS, INC. (US) | 2012-09-20 | — | — | US | disclosed |
| US-20120111411-A1 | FULLERENE DERIVATIVE | SUMITOMO CHEMICAL COMPANY, LTD. (JP) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150352108-A1 | AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF TBK1 AND/OR IKK EPSILON | TBK1, NFKBIA, CHUK | MEN1 4367/4885POLB 125/4885KMT2A 3692/4885 |
| US-20120238540-A1 | AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF IKK EPSILON AND/OR TBK1 | TBK1, NFKBIA, IKBKB | MEN1 4336/4885POLB 145/4885KMT2A 1946/4885 |
| US-20120111411-A1 | FULLERENE DERIVATIVE | HCN2, KCNN2, TMEM109 | MEN1 748/4885POLB 3461/4885KMT2A 2633/4885 |
| US-20240217978-A1 | COMPOUND AS ADENOSINE A2a RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | ADORA2A, ADORA1, ADORA2B | MEN1 2030/4885POLB 3154/4885KMT2A 2608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.